As the first treatment cleared by the FDA for Demodex blepharitis, an eye disease estimated to affect ... But, once Xdemvy’s twice-daily drops enter the picture, things take a turn for the ...
(NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the launch of a ...